A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients
- PMID: 11706098
- DOI: 10.1212/wnl.57.9.1595
A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients
Abstract
Background: Citicoline may reduce CNS ischemic injury by stabilizing cell membranes and reducing free radical generation. Previous safety and efficacy trials in patients who have had acute strokes suggested that citicoline may improve neurologic outcome with minimal side effects.
Objective: To determine the safety and efficacy of citicoline treatment in acute stroke patients.
Method: An 118-center, randomized, double-blind, efficacy trial in 899 patients compared placebo (n = 446) with citicoline (n = 453) (1000 mg PO twice a day) for 6 weeks, with a 6-week post-treatment follow-up period. Patients with acute (< or =24 hours) ischemic strokes clinically thought to be in the middle cerebral artery territory with NIH Stroke Scale (NIHSS) scores > or =8 were enrolled.
Results: Mean time to treatment was 13 hours for both groups and mean age was 67 years for those receiving placebo and 68 years for those receiving citicoline. Mean baseline NIHSS scores were 14.5 for placebo and 13.9 for citicoline (p = 0.06); medians were 14 for placebo and 13 for citicoline (p = 0.04). The incidence and type of side effects were similar between the groups. There were no between-group differences on the planned primary analysis, percent of patients with a > or =7-point NIHSS score change at 90 days (placebo 51%, citicoline 52%). There were no between-group differences on the other planned secondary analyses at 90 days, including mortality. However, post hoc analyses using standard "excellent recovery" measures suggested a possible treatment effect on the modified Rankin 0 or 1 (last observation carried forward: placebo 20%, citicoline 26%; p = 0.025) as well as a global outcome statistic.
Conclusions: Citicoline was safe but ineffective in improving the outcome of patients with acute ischemic stroke as measured by the planned analyses. Post hoc analyses suggest that a modest treatment effect may have been seen if more traditional analyses had been used.
Similar articles
-
A randomized efficacy trial of citicoline in patients with acute ischemic stroke.Stroke. 1999 Dec;30(12):2592-7. doi: 10.1161/01.str.30.12.2592. Stroke. 1999. PMID: 10582983 Clinical Trial.
-
Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial).Lancet. 2012 Jul 28;380(9839):349-57. doi: 10.1016/S0140-6736(12)60813-7. Epub 2012 Jun 11. Lancet. 2012. PMID: 22691567 Clinical Trial.
-
Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases.Methods Find Exp Clin Pharmacol. 2009 Apr;31(3):171-6. doi: 10.1358/mf.2009.31.3.1364241. Methods Find Exp Clin Pharmacol. 2009. PMID: 19536360 Clinical Trial.
-
The effects of citicoline on acute ischemic stroke: a review.J Stroke Cerebrovasc Dis. 2014 Aug;23(7):1764-9. doi: 10.1016/j.jstrokecerebrovasdis.2014.01.020. Epub 2014 Apr 13. J Stroke Cerebrovasc Dis. 2014. PMID: 24739589 Review.
-
Citicoline preclinical and clinical update 2009-2010.Stroke. 2011 Jan;42(1 Suppl):S36-9. doi: 10.1161/STROKEAHA.110.605568. Epub 2010 Dec 16. Stroke. 2011. PMID: 21164116 Review.
Cited by
-
Brain tissue salvage in acute stroke.Neurocrit Care. 2004;1(3):301-8. doi: 10.1385/NCC:1:3:301. Neurocrit Care. 2004. PMID: 16174927 Review.
-
Clinical trials for cytoprotection in stroke.NeuroRx. 2004 Jan;1(1):46-70. doi: 10.1602/neurorx.1.1.46. NeuroRx. 2004. PMID: 15717007 Free PMC article. Review.
-
Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis.Front Pharmacol. 2024 Nov 7;15:1475021. doi: 10.3389/fphar.2024.1475021. eCollection 2024. Front Pharmacol. 2024. PMID: 39575393 Free PMC article.
-
Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke.J Exp Pharmacol. 2015 Oct 1;7:17-28. doi: 10.2147/JEP.S63544. eCollection 2015. J Exp Pharmacol. 2015. PMID: 27186142 Free PMC article. Review.
-
Targeting oxidative stress for the treatment of ischemic stroke: Upstream and downstream therapeutic strategies.Brain Circ. 2016 Oct-Dec;2(4):153-163. doi: 10.4103/2394-8108.195279. Epub 2016 Dec 6. Brain Circ. 2016. PMID: 30276293 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical